Knight to Present at the 2019 RBC Capital Markets Global Healthcare Conference in New York City
MONTREAL, May 15, 2019 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, Samira Sakhia, President and Chief Financial Officer and Amal Khouri, Vice President of Business Development, are scheduled to participate in a fireside chat at the 2019 RBC Capital Markets Global […]
Knight Reports First Quarter 2019 Results
MONTREAL, May 09, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2019. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2019 Highlights Financials Revenues were $2,956, […]
GUD Day for Knight: Shareholders Vote Overwhelmingly in Favour of Management
MONTREAL, May 07, 2019 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”), a Canadian specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders (“Meeting”) held in Montreal, Quebec. Election of Directors Shareholders have voted in favour of all of management’s recommended director nominees listed in the Management Information […]
Notice of Knight Therapeutics’ First Quarter 2019 Results Conference Call
MONTREAL, May 02, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2019 financial results on Thursday, May 9, 2019 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto
MONTREAL, April 26, 2019 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer and Samira Sakhia, President and Chief Financial Officer, are scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at […]
Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast
MONTREAL, April 12, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country. Approved by Health Canada in April 2018, PROBUPHINE™ is the only subdermal implant designed to […]
Knight Reports 2018 Fourth Quarter and Year End Results
MONTREAL, March 14, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2018. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2018 Highlights Financial Results Revenues […]
Notice of Knight Therapeutics’ 2018 Fourth Quarter and Year End Results Conference Call
MONTREAL, March 07, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its 2018 fourth quarter and year end financial results on Thursday, March 14, 2019 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties […]
Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira“). The US$5 million secured […]
Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8
MONTREAL and BERWYN, Pa., Feb. 18, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8 Inc. (“Moksha8“), a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, today announced the closing of […]
